Promedior, Inc

Sangamo BioSciences, founded in 1995 and located in Richmond, Calif., is focused on the research and development of novel transcription factors for the regulation of gene expression. The company s most advanced therapeutic development program involves the use of transcription factors for the treatment of cardiovascular disease. Its other therapeutics development programs are focused on cancer, neuropathic pain, ophthalmic and infectious diseases. Sangamo s proprietary technology enables the engineering of transcription factors known as zinc finger DNA binding proteins. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors that can control gene expression and cell function. The company is developing ZFP TFs as a fundamentally enabling technology for commercial applications in human therapeutics, pharmaceutical discovery, agriculture and industrial biotechnology. More than 20 leading pharmaceutical and biotechnology companies have utilized Sangamo s research. The company trades on NASDAQ under the symbol SGMO.

SuperGen, Inc., a pharmaceutical company, engages in the development and commercialization of the therapies for solid tumors, hematological malignancies, and blood disorders. The company offers Orathecin capsules, a second-generation topoisomerase I inhibitor, which causes single-strand breaks in the DNA of rapidly dividing tumor cells; Dacogen, a pyrimidine analog that decreases the amount of methylation at certain DNA sites; and Nipentis that is used for the treatment of hairy cell leukemia, a type of B-lymphocytic leukemia, as well as shows activity in various autoimmune diseases, including GvHD, bone marrow transplantation and multiple sclerosis. It also offers Mitomycin, Paclitaxel, Mitozytrex, Inhaled Orathecin, Partaject Orathecin, CZ 112, and Cremophor-free paclitaxel for solid tumors; Daunorubicin for Acute leukemias; Surface Safe for surface decontaminate; Partaject busulfan for Neoplastic meningitis/bone marrow transplant; Avicine for Therapeutic Vaccine; and VEGF for anti-angiogenesis. The company sells its products to cancer hospitals, clinics, private practice oncology clinics, oncology distributors, and drug wholesalers in the United States. SuperGen was founded in 1991 and is headquartered in Dublin, California.